![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 22, 2021
The co-chairs reflect on key 2021 accomplishments, and share their thanks and best wishes for a happy New Year
December 22, 2021
This observational study aims to assess the effects of the pandemic as a barrier to enrollment in the TMIST breast cancer screening trial
December 22, 2021
The purpose of this new subcommittee, led by Kristen Spencer, DO, MPH, is to develop molecularly-informed concepts—particularly combination concepts
December 22, 2021
This trial aims to help define the optimal first-line treatment for patients with advanced, EGFR-mutant NSCLC and elucidate mechanisms of resistance to therapy
December 22, 2021
Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
December 22, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
November 16, 2021
Practice-changing trial results in melanoma; Group and committee leadership updates; remembering a dear colleague and friend
November 16, 2021
The phase 3 DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
November 16, 2021
In October, the ECOG-ACRIN Cancer Research Group lost one of its most trusted senior counsellors, Regulatory Officer Robert B. Catalano, PharmD
November 16, 2021
This pilot study is determining the feasibility and acceptability for adult and young adult participants patients between the ages of 18 and 39 in ECOG-ACRIN treatment trials to use the National Institutes of Health’s Patient-Reported Outcomes Measurement Information System (PROMIS®)
November 16, 2021
In an annual evaluation, 30 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 16, 2021
This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma